Learning from Big Pharma to Optimize Psychedelic Drug Development
May 18, 2022
During a post-earnings conference call yesterday, May 17th, executives Atai Live Sciences N.V. explained what they’ve learned from Johnson & Johnson’s Spravato launch. The launch of Spravato, an esketamine treatment, was marred by its high price, inpatient delivery, and addiction potential, despite its ability to reduce depression symptoms with a single dose. However, Atai’s CEO Florian Brand intends to apply the lessons learned to the company’s own ketamine-based treatments.
According to Atai’s CEO Florian Brand, “I think it’s important to emphasize that we’re differentiated from esketamine in our target profile but also commercial profile that you mentioned is differentiated from SPRAVATO and esketamine with our ketamine that we are developing for at-home use. Having said this, a lot of our therapies are, of course, thought to be administered in the clinic. For instance, our DMT program. And so observing what J&J’s SPRAVATO has done, it tells a lot of things that we can build upon and learn from.”
To learn more, click here.
(Source: Bezinga, May 18th, 2022)